Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Moreno

Showing results (121-130 of 167) with videos related to

Pageof 17
Sort By:
Blood|August 20, 2009
Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cellsTill Seiler, Manuela Woelfle, Sophia Yancopoulos, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 12, 2020
Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?Isabel González-Gascón-Y-Marín, Carolina Muñoz-Novas, Iñigo Figueroa, et al.
Hypertension (Dallas, Tex. : 1979)|November 28, 2012
Increased proliferative cells in the medullary thick ascending limb of the loop of Henle in the Dahl salt-sensitive ratChun Yang, Francesco C Stingo, Kwang Woo Ahn, et al.
European Journal of Haematology|April 14, 2023
Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBISara Redondo, Irene García-Cadenas, Antonio Vila, et al.
Blood Advances|April 4, 2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Leukemia|October 20, 2019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyJan A Burger, Paul M Barr, Tadeusz Robak, et al.
Blood|October 26, 2007
Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesisFiona Murray, Nikos Darzentas, Anastasia Hadzidimitriou, et al.
Future Oncology (London, England)|January 9, 2023
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language SummaryPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
The Lancet. Oncology|December 8, 2018
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Haematologica|January 29, 2008
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphomaSilvia Montoto, Carol Moreno, Eva Domingo-Doménech, et al.
Pageof 17

Showing results (121-130 of 167) with videos related to

Sort By:
Pageof 17
Blood|August 20, 2009
Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cellsTill Seiler, Manuela Woelfle, Sophia Yancopoulos, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 12, 2020
Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?Isabel González-Gascón-Y-Marín, Carolina Muñoz-Novas, Iñigo Figueroa, et al.
Hypertension (Dallas, Tex. : 1979)|November 28, 2012
Increased proliferative cells in the medullary thick ascending limb of the loop of Henle in the Dahl salt-sensitive ratChun Yang, Francesco C Stingo, Kwang Woo Ahn, et al.
European Journal of Haematology|April 14, 2023
Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBISara Redondo, Irene García-Cadenas, Antonio Vila, et al.
Blood Advances|April 4, 2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
Leukemia|October 20, 2019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyJan A Burger, Paul M Barr, Tadeusz Robak, et al.
Blood|October 26, 2007
Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesisFiona Murray, Nikos Darzentas, Anastasia Hadzidimitriou, et al.
Future Oncology (London, England)|January 9, 2023
Many People With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Benefit From Ibrutinib Treatment Up To 8 Years: A Plain Language SummaryPaul M Barr, Carolyn Owen, Tadeusz Robak, et al.
The Lancet. Oncology|December 8, 2018
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialCarol Moreno, Richard Greil, Fatih Demirkan, et al.
Haematologica|January 29, 2008
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphomaSilvia Montoto, Carol Moreno, Eva Domingo-Doménech, et al.
Pageof 17